Tabula Rasa HealthCare Inc (NASDAQ:TRHC) has received an average recommendation of “Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $82.44.
Several research analysts have issued reports on TRHC shares. Zacks Investment Research lowered Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research note on Saturday, November 10th. BidaskClub lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 15th. Cantor Fitzgerald restated a “buy” rating and set a $99.00 target price on shares of Tabula Rasa HealthCare in a report on Tuesday, November 6th. Chardan Capital increased their target price on Tabula Rasa HealthCare from $77.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, Robert W. Baird restated a “buy” rating and set a $70.00 target price on shares of Tabula Rasa HealthCare in a report on Wednesday, August 8th.
Tabula Rasa HealthCare stock opened at $65.33 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.49 and a quick ratio of 0.46. Tabula Rasa HealthCare has a 52-week low of $27.25 and a 52-week high of $91.16. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -1,633.25, a P/E/G ratio of 6.04 and a beta of 2.58.
In other Tabula Rasa HealthCare news, President Orsula V. Knowlton bought 7,500 shares of the firm’s stock in a transaction dated Monday, November 12th. The shares were bought at an average price of $65.00 per share, for a total transaction of $487,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $85.98, for a total value of $687,840.00. The disclosure for this sale can be found here. Insiders have sold 48,000 shares of company stock worth $3,638,560 in the last 90 days. Company insiders own 14.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in TRHC. Comerica Bank bought a new position in Tabula Rasa HealthCare in the second quarter valued at about $947,000. Citadel Advisors LLC boosted its holdings in Tabula Rasa HealthCare by 47.0% in the second quarter. Citadel Advisors LLC now owns 8,855 shares of the company’s stock valued at $565,000 after acquiring an additional 2,832 shares during the last quarter. Pitcairn Co. bought a new position in Tabula Rasa HealthCare in the second quarter valued at about $285,000. Rhumbline Advisers boosted its holdings in Tabula Rasa HealthCare by 34.5% in the second quarter. Rhumbline Advisers now owns 36,119 shares of the company’s stock valued at $2,305,000 after acquiring an additional 9,272 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in Tabula Rasa HealthCare by 29.7% in the second quarter. BlackRock Inc. now owns 2,119,507 shares of the company’s stock valued at $135,288,000 after acquiring an additional 484,979 shares during the last quarter. Institutional investors own 78.17% of the company’s stock.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Read More: No Load Funds
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.